# Phase I Clinical Trial of 68Ga-NOTA-SNA002

> **NCT05989997** · PHASE1 · COMPLETED · sponsor: **SmartNuclide Biopharma** · enrollment: 17 (actual)

## Conditions studied

- Solid Tumor
- Positron-Emission Tomography(PET)

## Interventions

- **DRUG:** 68Ga-NOTA-SNA002

## Key facts

- **NCT ID:** NCT05989997
- **Lead sponsor:** SmartNuclide Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-01
- **Primary completion:** 2024-11-08
- **Final completion:** 2024-11-08
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05989997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05989997, "Phase I Clinical Trial of 68Ga-NOTA-SNA002". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05989997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*